



US 20210032327A1

(19) **United States**(12) **Patent Application Publication**
AB et al.(10) **Pub. No.: US 2021/0032327 A1**(43) **Pub. Date: Feb. 4, 2021**(54) **FOLATE RECEPTOR 1 ANTIBODIES AND
IMMUNOCONJUGATES AND USES
THEREOF**filed on May 20, 2010, provisional application No.
61/413,172, filed on Nov. 12, 2010.(71) Applicant: **ImmunoGen, Inc.**, Waltham, MA (US)(72) Inventors: **Olga AB**, Millis, MA (US); **Daniel
Tavares**, Natick, MA (US); **Lingyun
Rui**, Weston, MA (US); **Gillian Payne**,
Waban, MA (US); **Viktor S.
Goldmakher**, Newton, MA (US)(73) Assignee: **ImmunoGen, Inc.**, Waltham, MA (US)(21) Appl. No.: **16/934,143**(22) Filed: **Jul. 21, 2020****Related U.S. Application Data**(60) Continuation of application No. 16/384,031, filed on
Apr. 15, 2019, now Pat. No. 10,752,683, which is a
division of application No. 15/583,281, filed on May
1, 2017, now Pat. No. 10,301,385, which is a division
of application No. 14/819,209, filed on Aug. 5, 2015,
now Pat. No. 9,657,100, which is a division of
application No. 13/800,835, filed on Mar. 13, 2013,
now Pat. No. 9,133,275, which is a division of
application No. 13/033,723, filed on Feb. 24, 2011,
now Pat. No. 8,557,966.(60) Provisional application No. 61/307,797, filed on Feb.
24, 2010, provisional application No. 61/346,595,**Publication Classification**(51) **Int. Cl.****C07K 16/28** (2006.01)
A61K 47/68 (2006.01)
A61K 47/54 (2006.01)
A61K 39/395 (2006.01)
A61K 45/06 (2006.01)
C07K 16/30 (2006.01)
A61K 31/5365 (2006.01)
A61K 31/537 (2006.01)(52) **U.S. Cl.**CPC **C07K 16/28** (2013.01); **A61K 47/6889**
(2017.08); **A61K 47/545** (2017.08); **A61K**
47/6803 (2017.08); **A61K 47/6849** (2017.08);
A61K 39/39558 (2013.01); **C12N 15/63**
(2013.01); **C07K 16/3069** (2013.01); **C07K**
16/30 (2013.01); **A61K 31/5365** (2013.01);
A61K 39/3955 (2013.01); **A61K 47/6851**
(2017.08); **A61K 31/537** (2013.01); **A61K**
45/06 (2013.01)

(57)

ABSTRACTNovel anti-cancer agents, including, but not limited to,
antibodies and immunoconjugates, that bind to human folate
receptor 1 are provided. Methods of using the agents,
antibodies, or immunoconjugates, such as methods of inhib-
iting tumor growth are further provided.**Specification includes a Sequence Listing.**